- Home
- RLMD vs RCKT Comparison
RLMD vs RCKT Comparison
Compare RLMD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- RCKT
- Stock Information
- Founded
- RLMD 2004
- RCKT 1999
- Country
- RLMD United States
- RCKT United States
- Employees
- RLMD N/A
- RCKT N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- RCKT Health Care
- Exchange
- RLMD Nasdaq
- RCKT Nasdaq
- Market Cap
- RLMD 289.7M
- RCKT 340.9M
- IPO Year
- RLMD N/A
- RCKT N/A
- Fundamental
- Price
- RLMD $3.98
- RCKT $3.05
- Analyst Decision
- RLMD Hold
- RCKT Buy
- Analyst Count
- RLMD 2
- RCKT 13
- Target Price
- RLMD $1.00
- RCKT $12.88
- AVG Volume (30 Days)
- RLMD 1.8M
- RCKT 1.9M
- Earning Date
- RLMD 11-13-2025
- RCKT 11-06-2025
- Dividend Yield
- RLMD N/A
- RCKT N/A
- EPS Growth
- RLMD N/A
- RCKT N/A
- EPS
- RLMD N/A
- RCKT N/A
- Revenue
- RLMD N/A
- RCKT N/A
- Revenue This Year
- RLMD N/A
- RCKT N/A
- Revenue Next Year
- RLMD N/A
- RCKT $3,582.16
- P/E Ratio
- RLMD N/A
- RCKT N/A
- Revenue Growth
- RLMD N/A
- RCKT N/A
- 52 Week Low
- RLMD $0.24
- RCKT $2.19
- 52 Week High
- RLMD $4.34
- RCKT $15.95
- Technical
- Relative Strength Index (RSI)
- RLMD 78.00
- RCKT 37.09
- Support Level
- RLMD $2.42
- RCKT $3.10
- Resistance Level
- RLMD $2.86
- RCKT $3.37
- Average True Range (ATR)
- RLMD 0.43
- RCKT 0.20
- MACD
- RLMD 0.15
- RCKT -0.07
- Stochastic Oscillator
- RLMD 82.19
- RCKT 3.43
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.